Kyowa Kirin To Offload Selected Mature Portfolio To Grünenthal
New JV Set For '26 Buy-Out
The Japanese and German firms agree to establish a joint company to handle 13 mature brands from Kyowa Kirin's portfolio, mainly focused on pain management and including Abstral and PecFent. Grünenthal will own 51% and plans to fully buy out the operation in early 2026.
You may also be interested in...
Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
Next-Gen Gene Therapy Firm Kate Therapeutics Starts Out With Big Pharma Partner
Kate is focused on delivering gene therapies for two rare, neuromuscular diseases by deploying AAV technology that it says will target muscle tissue and enable smaller therapeutic payloads.
Shionogi Renews 10-Year Goal After Infectious Disease Success
Shionogi renews its 10-year strategic plan originally announced in 2020 following the successful debut of COVID-19 therapeutic Xocova. Fulfilling its 2025 goals earlier, its new strategy covers HIV and COVID-19 products with more new products to be launched.